Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
EBITDA Over TimeStrong
Percentile Rank86
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-21.08M
↑ 35% vs avg
Percentile
P86
Within normal range
Streak
1 yr
Consecutive declineStrong
Average
$-32.57M
Historical baseline
PeriodValueYoY Change
2025$-21.08M-1.0%
2024$-20.87M+13.2%
2023$-24.04M-10.3%
2022$-21.79M+54.9%
2021$-48.34M-98.0%
2020$-24.41M+32.0%
2019$-35.88M+4.9%
2018$-37.72M-1.0%
2017$-37.36M+31.1%
2016$-54.21M-